is a procedure that involves biopsying the embryos and identifying which of the embryos is at risk of a specific genetic disease, such as cystic fibrosis.

Pre-implantation genetic screening (PGS) can also be used to screen for embryos with an abnormal number of chromosomes –with a view to increasing the likelihood of an ongoing pregnancy. The main indications for PGS are an advanced maternal age, a history of recurrent miscarriages or repeated unsuccessful implantation. It has also been proposed for patients with obstructive and non-obstructive azoospermia.

One or two cells are biopsied from the embryos and then flown to a world-leading laboratory in the United States. They perform the genetic analysis and get the results back to us within 24 hours –and this aids in selecting which embryos are likely to be free from the genetic disease

After the embryo replacement, surplus good quality unaffected embryos can be vitrified for use in future / sibling cycles.

This represents a significant coming together of state of the art technologies :

Micromanipulation techniques and technology which enable ICSI to create the embryos and to then perform the embryo biopsy

Genetic Screening – to help in selecting which embryos are likely to be free from the genetic disease.

Vitrification – to store surplus embryos are likely to be free from the genetic disease for future use and siblings.